Neutre
Johnson & Johnson's Q2 2026 earnings beat estimates; stock rises 1.2% to $255.66.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Johnson & Johnson reported strong Q2 2026 results, with earnings per share (EPS) of $2.90, surpassing analyst expectations of $2.84. The company also raised its 2026 guidance, projecting reported sales of $101.1 billion, a 7.3% increase at the midpoint. Despite these positive developments, the stock experienced a slight decline due to underperformance in the MedTech segment.
Points clés
- Q2 2026 EPS of $2.90 exceeds analyst expectations of $2.84.
- Raised 2026 guidance with projected sales of $101.1 billion, up 7.3%.
- MedTech segment underperformed, leading to a slight stock decline.
- Analysts maintain a "Moderate Buy" rating with a $265.30 target price.
Sources
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlookNasdaq · July 15, 2026
- Johnson & Johnson (JNJ) Stock Faces Margin Squeeze As Q2 Net Profitability Undercuts Bullish NarrativeSimply Wall St News · July 17, 2026
- Johnson & Johnson (NYSE:JNJ) Shares Up 1.2% - Here's What HappenedMarketBeat · July 17, 2026
- J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's WhyTradingView News · July 17, 2026
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
